Investors sold shares of Gilead Sciences Inc. (NASDAQ:GILD) on strength during trading on Friday. $99.32 million flowed into the stock on the tick-up and $127.18 million flowed out of the stock on the tick-down, for a money net flow of $27.86 million out of the stock. Of all stocks tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.41 for the day and closed at $81.00

Several equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 4th. JPMorgan Chase & Co. restated a “buy” rating on shares of Gilead Sciences in a research report on Saturday, May 14th. Jefferies Group restated a “hold” rating and set a $96.00 price objective on shares of Gilead Sciences in a research report on Wednesday, June 29th. Royal Bank Of Canada restated a “buy” rating on shares of Gilead Sciences in a research report on Saturday, April 30th. Finally, Oppenheimer Holdings Inc. restated a “buy” rating and set a $116.00 price objective (down from $120.00) on shares of Gilead Sciences in a research report on Wednesday, May 4th. Ten research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $107.37.

The company has a 50 day moving average of $82.88 and a 200 day moving average of $87.37. The company has a market cap of $106.89 billion and a P/E ratio of 7.11.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. During the same quarter last year, the company posted $3.15 earnings per share. The business had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. Equities research analysts predict that Gilead Sciences Inc. will post $11.78 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.32%. The ex-dividend date is Wednesday, September 14th.

In related news, EVP Paul Rutherford Carter sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $87.02, for a total transaction of $174,040.00. Following the sale, the executive vice president now directly owns 63,122 shares of the company’s stock, valued at approximately $5,492,876.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO John F. Milligan sold 112,000 shares of the company’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $86.94, for a total value of $9,737,280.00. Following the sale, the chief executive officer now directly owns 1,170,963 shares in the company, valued at $101,803,523.22. The disclosure for this sale can be found here.

Other large investors have recently bought and sold shares of the company. Sfmg LLC raised its stake in Gilead Sciences by 5.2% in the fourth quarter. Sfmg LLC now owns 10,619 shares of the biopharmaceutical company’s stock valued at $1,075,000 after buying an additional 522 shares in the last quarter. Mizuho Trust & Banking Co. Ltd. raised its stake in Gilead Sciences by 1.0% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 2,277,664 shares of the biopharmaceutical company’s stock valued at $232,686,000 after buying an additional 23,105 shares in the last quarter. TMD & Associates Inc. purchased a new stake in Gilead Sciences during the fourth quarter valued at about $2,539,000. Synovus Financial Corp raised its stake in Gilead Sciences by 8.0% in the fourth quarter. Synovus Financial Corp now owns 98,651 shares of the biopharmaceutical company’s stock valued at $9,964,000 after buying an additional 7,307 shares in the last quarter. Finally, Edgemoor Investment Advisors Inc. raised its stake in Gilead Sciences by 1.1% in the fourth quarter. Edgemoor Investment Advisors Inc. now owns 176,263 shares of the biopharmaceutical company’s stock valued at $17,836,000 after buying an additional 1,857 shares in the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.